Bristow Group’s 22.8% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $47.58 per share. This performance may have investors wondering how to approach the situation.

Lucid unleashed a number of news developments on investors last week, but the stock has declined steeply since. Here's why.

Regarded as defensive investments, consumer staples stocks are generally safe bets in choppy markets. The flip side is that they frequently fall behind growth industries when times are good, and this perception became a reality over the past six months as

The AI industry's mudslinging continues.

Target has had an impressive run over the past six months as its shares have beaten the S&P 500 by 32.1%. The stock now trades at $130.16, marking a 37.9% gain. This was partly due to its solid quarterly results, and the run-up might have investors contem

Why are the major indexes down on a quiet news day? Apple's leadership shakeup is doing most of the heavy lifting.

These companies have stood the test of time.

Genco has been on fire lately. In the past six months alone, the company’s stock price has rocketed 54%, reaching $24.18 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the si

It takes guts to buy an underperforming stock.

Lumen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 15.6%. The stock now trades at $8.70, marking a 21.3% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contem

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reli

Toast shares have been hammered this year.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

SanDisk and Western Digital have crushed the market over the past year, but one of them looks more suited to extend its rally.

This biotech focused on precision medicines for cancer and immune disorders disclosed a notable insider sale after a strong year for shares.